What is Chardan Capital's Forecast for COYA FY2025 Earnings?

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities researchers at Chardan Capital decreased their FY2025 earnings per share estimates for shares of Coya Therapeutics in a report released on Wednesday, May 14th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($1.57) per share for the year, down from their previous forecast of ($1.03). Chardan Capital currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share.

Other analysts have also issued reports about the company. D. Boral Capital reissued a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Tuesday, April 22nd. Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat, Coya Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

Coya Therapeutics Stock Performance

COYA stock traded up $0.19 during trading on Monday, reaching $5.90. 12,660 shares of the company traded hands, compared to its average volume of 72,712. The company has a market capitalization of $98.68 million, a price-to-earnings ratio of -9.08 and a beta of 0.49. The business has a 50 day simple moving average of $5.97 and a 200 day simple moving average of $6.13. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $257.88 million for the quarter, compared to analysts' expectations of $2.63 million.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after acquiring an additional 4,777 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Coya Therapeutics during the first quarter worth approximately $65,000. XTX Topco Ltd acquired a new stake in Coya Therapeutics during the 4th quarter worth $59,000. Jane Street Group LLC bought a new position in shares of Coya Therapeutics during the fourth quarter worth $74,000. Finally, Northern Trust Corp boosted its stake in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the period. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.